chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID 19; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (COVID 19) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID 19). At the time of the report, COVID-19 (COVID 19) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was provided. Patient received treatment.    Reporter did not allow further contact
Screaming from about 4:15pm to 8:30/9 pm. Nothing helped. Everyone I moved her it got worse. Her legs were weak and if I tried to sit her down it appeared that her but was in pain too.
Severe dizziness, vision  Fast heart beat Chills Fever Runny nose Migraine
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 36-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 23Apr2021 as dose 1, single (Lot number: EW0170), in left arm, on 15May2021 as dose 2, single (Lot number: EW0183), in left arm and on 29Dec2021 as dose 3 (booster), single (Lot number: FJ1611) at the age of 36 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Graves Disease" (unspecified if ongoing), notes: Graves Disease with active hyperthyroidism; "hyperthyroidism" (unspecified if ongoing), notes: Graves Disease with active hyperthyroidism. Concomitant medication(s) included: METHIMAZOLE, start date: 06Oct2021; CITALOPRAM, start date: 01Dec2021; GUANFACINE, start date: 01Dec2021. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 29May2022, outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (29May2022) Positive, notes: symptoms were nearly gone but covid test was positive (very pale pink); (31May2022) Positive, notes: symptoms came back fully and tested positive (solid pink). Therapeutic measures were taken as a result of vaccination failure, covid-19.  Addition information: Treatment start date was 24May2022. Treatment stop date was 29May2022. Known allergies was no.
RECEIVED HALF DOSE FOR THEIR BOOSTER DOSE; OFF LABEL USE; This spontaneous report received from a health care professional concerned a 32 year old male of unknown race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient previously received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date for prophylactic vaccination (Dose number in series 1).  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1822809 or 211A21A expiry: unknown) dose was not reported, 1 total, administered on 27-NOV-2021 for prophylactic vaccination (Dose number in series 2). No concomitant medications were reported. HCP (health care provider) called to advise a patient that received a half dose of the Janssen COVID-19 vaccine for their booster dose On 27-NOV-2021 (vaccine underdose) and had off label use. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the received half dose for their booster dose and off label use was not reported This report was non-serious. This case, from the same reporter is linked to 20211202250, 20211201046, 20211202193, 20211201228, 20211201168, 20211200752, 20211201351, 20211200994, 20211201450, 20211202199, 20211202469, 20211204104, 20211202379, 20211201082, 20211202515, 20211200675, 20211201304, 20211201392, 20211201443, 20211201963, 20211202161, 20211200717, 20211200723, 20211200769, 20211201362, 20211202207, 20211202246, 20211202371, 20211220152, 20211220146, 20211220262, 20211220250, 20211220145, 20211220619, 20211219926 and 20211220155.
Warm to touch, red, raised. Patient also reported nausea and vomiting, no fever, but wasn't sure if it was related to the vaccines or the stomach bug.
I was positive for COVID-19 within 24 hours of receiving my dose 4 on 04/24/2022 with symptoms of cough, chills, fatigue, I felt feverish, and my feet were hot and tingly. I was not prescribed any medication. I was ill for 5 days before my symptoms began to resolve. I am fully recovered, but I had lingering fatigue for 2 months.
This spontaneous report as received from a Nurse refers to unspecified number of patients of unknown age. The reporter stated that VAQTA, which might have gone out of range sometime in April 2013, but nurse was unable to provide the worst case time frame or temperature. The nurse additionally stated that an unspecified number of people have been administered this product. No adverse effects have been reported. Lot numbers and expiration dates unavailable for this product. On 10-JUN-2014, a phone call was placed to the nurse. The phone call was answered by other reporter. The reporter stated there was no one by that name at their facility/office. She checked with other nursing/office personnel concerning vaccine storage issues from April 2013. There was no information available to share with company concerning this report. This is one of several reports. The case is linked to 1309USA013801, 1406USA007118, 1406USA007119, 1406USA007120, 1406USA007121, 1406USA007076 (same reporter link). Additional information has been requested.
Information has been received from a registered nurse concerning a 14 year old female with asthma who on 26-OCT-2006 was vaccinated with the first 0.5 ml dose of GARDASIL vaccine (yeast), (Lot # 653735/0688P). On 12-28-06, the patient was vaccinated with the second 0.5 ml dose of GARDASIL vaccine (yeast) (Lot # 654389/0916F). The nurse reported that the patient had adverse experiences after vaccination. The patient experienced neck pain. Also, the patient's arm "had hurt all the way down, off and on". At the time of the report the patient's symptoms began after the first and second dose of GARDASIL vaccine (yeast). At the time of the report, the symptoms had not resolved. The nurse also mentioned that the patient participated in gymnastics. Additional information has been requested. This is in follow-up to report(s) previously submitted on 3/14/2007. Since her initial injection, on 26-OCT-2006 (AE onste date also reported on 17-FEB-2007).
Somewhere between 13th to 15th they go the covid virus./vaccine on 01 FEB 2021; Somewhere between 13th to 15th they go the covid virus./vaccine on 01 FEB 2021; my mom ended up with it(cold) as well; This is a spontaneous report received from a contactable consumer. A 70-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 1 via an unspecified route of administration on 01Feb2021 to 01Feb2021 as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. It was reported that calling on behalf of his parents who received the first dose of the Pfizer covid vaccine on 01Feb2021. Somewhere between 13th to 15th they go the covid virus. His father felt like he had a cold, gave him the test and then his mom ended up with it as well on Feb2021. The efficacy of the first dose, feel like they were very well protected. Neither cases were bad, they did get the monoclonal antibodies, they were supposed to wait 90 days, it was not their recommendation, it was the CDC recommendation. I thought would call Pfizer since it was related to the Pfizer vaccine. The events "somewhere between 13th to 15th they go the covid virus./vaccine on 01 FEB 2021" were considered as medically significant. The outcome of the events was unknown.   Information about batch and lot number has been requested.
PATIENT COMPLAINED OF PAIN AT INJECTION SITE TO THE POINT WHERE HE CANNOT LIFT HIS ARM.
I woke up with very bad headache and feeling nauseous 18 hours after receiving second dose
Joint pain after first shot; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Joint pain after first shot) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (Joint pain after first shot). At the time of the report, ARTHRALGIA (Joint pain after first shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. No treatment information were provided.   This case was linked to MOD-2021-345905 (Patient Link).
Local reaction right thigh. Erythema 3in in diameter. Site hard and hot to touch. C/o mild pain. Prednisone 20mg, 1 tab x 5 days and amoxicillin 500/125 x 10 days.
Experienced fatigue and drowsiness five minutes after the flu shot. Five hours later, took a brief nap and woke up wheezing and finding it very difficult to breathe. Wheezing faded after a few hours or so.
on 06/18/2021 my husband suffered a central brain aneurysm and passed away om 06/19/2021
developed myocarditis after a second dose of the Pfizer mRNA COVID-19 vaccine; This is a literature report for the following literature source(s): "RECOGNIZING AND MANAGING MYOCARDITIS FOLLOWING COVID-19 VACCINATION: MITIGATING RISK OF SUDDEN CARDIAC DEATH IN ATHLETES", Journal of the College of Cardiology, 2022; Vol:79 (9), pgs:2397, DOI:10.1016/S0735-1097%2822%2903388-5.  A 19 year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "COVID-19 infection" (unspecified if ongoing), notes: 6-8 months prior; with symptoms that included rhinorrhea, cough, anosmia, ageusia, and mild chest pain. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st single dose), for COVID-19 immunisation. The following information was reported: MYOCARDITIS (medically significant, life threatening), outcome "recovering", described as "developed myocarditis after a second dose of the Pfizer mRNA COVID-19 vaccine". The event "developed myocarditis after a second dose of the pfizer mrna covid-19 vaccine" was evaluated at the emergency room visit. The patient underwent the following laboratory tests and procedures: angiogram: normal; blood thyroid stimulating hormone: normal; c-reactive protein: normal; echocardiogram: normal left ventricular systolic function, notes: normal wall motion, and no pericardial effusion; electrocardiogram: 0.5-1mm st segment elevation in the inferior and, notes: and lateral leads; full blood count: normal; magnetic resonance imaging: minimal t2 signal elevation, but did reveal late, notes: gadolinium enhancement of 25-75 percentage of the inferior and lateral walls; metabolic function test: normal; physical examination: normal; sars-cov-2 test: positive; troponin: 3.61 ng/ml, notes: elevated and peaked; vital signs measurement: normal. Therapeutic measures were taken as a result of myocarditis included ibuprofen and beta blocker.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of the reported events MYOCARDITIS Cannot be excluded  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate
Information has been received from a registered nurse concerning a 19 year old Asian male with an allergy to procaine hydrochloride (NOVOCAIN) and no other pertinent medical history who on 18-JUL-2005 at 15:00 was vaccinated SC with a first dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live.  There was no concomitant medication.  There was no illness at the time of vaccination.  On 19-JUL-2005 at 11:00 the patient returned to the office with a generalized flat macular rash on his trunk and arms.  Unspecified medical attention was sought.  No laboratory or diagnostic tests were performed.  Treatment included calamine lotion.  The patient recovered on 22-JUL-2005.  There was no product quality complaint involved.  Additional information has been requested.
This spontaneous report was received from a Doctor of pharmacy concerning a patient of unknown age and gender. On 18-SEP-2012, the patient was inadvertently vaccinated with an expired dose of PNEUMOVAX 23, intramuscularly. Lot number and expiry date was reported as 669579/0595AA and 31-AUG-2012 respectively. No concomitant medications were reported. No adverse effect was reported. Additional information has been requested.
2 months old child received the vaccine; This case was reported by a other health professional and described the occurrence of inappropriate age at vaccine administration in a 2-month-old male patient who received DTPa-IPV (Kinrix) (batch number 24T2N, expiry date 7th May 2023) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 10th September 2021, the patient received the 1st dose of Kinrix and Kinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient received dose of Kinrix in the left deltoid. The health care professional reported that, 2 months old patient received dose of Kinrix, which led to inappropriate age at vaccine administration. The reporter consented to follow up by phone.
the patient got COVID-19; the patient got COVID-19; autoimmune skin disease; eczema; burning skin; Feb2021 with dose 2, and Aug2021 with dose 3 (booster) of Moderna COVID-19 vaccine; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): 2023NVX-US-000001258 (NOVAVAX).  A 72-year-old female patient received bnt162b2 (BNT162B2), in Jan2021 as dose 1, single (Batch/Lot number: unknown), in Feb2021 as dose 2, single (Batch/Lot number: unknown) and in May2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 72 years for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), in Aug2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset Aug2021, outcome "unknown", described as "Feb2021 with dose 2, and Aug2021 with dose 3 (booster) of Moderna COVID-19 vaccine"; DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "the patient got COVID-19"; AUTOIMMUNE DISORDER (medically significant), outcome "unknown", described as "autoimmune skin disease"; ECZEMA (non-serious), outcome "unknown"; SKIN BURNING SENSATION (non-serious), outcome "unknown", described as "burning skin". The events "autoimmune skin disease", "eczema" and "burning skin" required physician office visit. Clinical course: It was reported after the Pfizer booster, on unreported dates, the patient got COVID-19. She also got a weird eczema and burning skin. She went to the dermatologist. The dermatologist stated she now has an autoimmune skin disease and was seeing more of this in her medical practice. She also stated she thinks the mRNA vaccines were the cause.  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.
Information was received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's medical history, concurrent conditions or concomitant medications. On or about 24-JUL-2009, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration unknown), as recommended for routine adult health maintenance and the prevention of shingles. It was reported that the vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 11-MAR-2011, the patient was treated by a physician for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as herpes zoster, or shingles. The patient has experienced significant pain and complication from her shingles infections, rendering her homebound since 2013. She had been prescribed valacyclovir hydrochloride (VALTREX) and acetaminophen hydrocodone bitartrate (VICODIN) for management of her painful symptoms.  As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment.  As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The events shingles, immune system disorder, and vaccination failure were considered disabling as they rendered the patient homebound. Additional information has been requested.
had her neck swell up like a balloon; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (had her neck swell up like a balloon) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SWELLING (had her neck swell up like a balloon). At the time of the report, SWELLING (had her neck swell up like a balloon) outcome was unknown.            No concomitant medication was reported. No treatment medication was reported.
The needle was originally jammed into the bone in my left arm, pulled out some and injected. 3 hours after injection I had a fever of 101.4, head ache, body ache. Throughout the night had night sweats, chills, constant fever, hard to breathe, headache, body aches.
On 11-17-21, suffered stroke caused by a blood clot that went thru a hole in the heart
Right upper arm red, hot, swollen with bullae present over area given initial prescription for Augmentin, then to Keflex and Prelone.
First dose was in January and experienced COVID arm.  Second dose (this one) had severe body pain, chills, shivers and low-grade temperature.  Then, in August, 2021,  experienced severe chest pain and was hospitalized for a spontaneous coronary artery dissection, or a non-stemi heart attack.
This spontaneous report as received from a physician via company representative refers to a 16 year old female patient. On 15-JUL-2013 the patient was vaccinated with the first dose of GARDASIL (lot # was not reported) by injection route for prevention of HPV. It was reported that after patient received vaccination, she then sat in the physician's office for 10 to 15 minutes afterward before being released. On 15-JUL-2013 she fainted at the front of the physician's office as she was leaving. As a result of the fainting, the patient was treated by being kept in the office for an additional 30 minutes, and then her "vitals were taken" before he was released. The taking of the patient's vitals was the only testing performed and no result provided. The patient did not seek medical attention. The outcome of fainted was reported as recovered on 15-JUL-2013. Additional information has been requested.
Temperature 97.5 ax. Pulse 100, Resp 24 - swollen erythematous right testicle, tender to touch, testes descended bilaterally.
SkinRash, UrticariaPruritus, TIGHTNESS IN THROAT Narrative:  EMPLOYEE REPORTED TIGHTNESS IN THROAT WIT ITCHING AT APPROXIMATELY 10:00AM AND EPI IM WAS ADMINISTERED
Pt recvd vax, had a repeat of crying episode lasted 3-4 hrs. Reported to hlth dept.
April 9 , red at injection site April 10, Fever 100 degrees.  Right arm tender, warm to touch, swollen, itchy, and red 4" x 5" rash down arm. April 12, Rash 7" x 7" down arm and itchy. April 16,  Rash still same size. Still itchy. April 17,  Itchy. Upper rash at injection gone. but still red lower. April 19, Rash gone, but arm still itchy.
Within 30 hrs. pt had nausea, vomiting, low grade fever and chills accompanied the next 24 hrs. with headache and general ill-feeling. The 3rd days after vaccination there was no more nausea or vomiting; the other symptoms lessened, and were gone by 4th day.
This spontaneous report was received from a medical assistant referring to an unspecified number of unspecified patients of unknown age and gender. Information about the patients medical histories and concurrent conditions was not provided. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL (administration routes, lot numbers and expiration dates were not provided). No concomitant therapies were reported. No adverse effect reported. It was unknown if the patients sought medical attention. No product quality complaint was involved. This is one of several reports from the same reporter. Additional information has been requested.
Generalized urticaria (hives) about 15 min after immunizations. No other sxs. Treated with Epinephrine SC and Benadryl oral . Resolved.